Cargando…

A Review of Telmisartan in the Treatment of Hypertension: Blood Pressure Control in the Early Morning Hours

Measurement of blood pressure in the clinic may provide a false impression of blood pressure control. Ambulatory blood pressure monitoring (ABPM) allows the automatic recording of the circadian variation in blood pressure and evaluation of the efficacy of antihypertensive medication throughout the d...

Descripción completa

Detalles Bibliográficos
Autor principal: Gosse, Philippe
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993985/
https://www.ncbi.nlm.nih.gov/pubmed/17326326
_version_ 1782135461892849664
author Gosse, Philippe
author_facet Gosse, Philippe
author_sort Gosse, Philippe
collection PubMed
description Measurement of blood pressure in the clinic may provide a false impression of blood pressure control. Ambulatory blood pressure monitoring (ABPM) allows the automatic recording of the circadian variation in blood pressure and evaluation of the efficacy of antihypertensive medication throughout the dosing interval. Ambulatory blood pressure provides more effective prediction of cardiovascular risk; blood pressure control at the time of heightened risk in the early morning after waking and before taking the next dose of medication is becoming important in order to improve long-term prognosis. To achieve blood pressure control in the early morning, a long-acting antihypertensive agent is essential. Telmisartan, an angiotensin II receptor blocker, as well as having a terminal elimination halflife of 24 h, has a large volume of distribution due to its high lipophilicity. The efficacy of telmisartan 80 mg monotherapy has been demonstrated using ABPM, with superior reduction in mean values for the last 6 h of the dosing interval compared with ramipril 10 mg and valsartan 80 mg. In addition, telmisartan 80 mg provides superior blood pressure control after a missed dose compared with valsartan 160 mg. When combined with hydrochlorothiazide (HCTZ) 12.5 mg, telmisartan 40 mg and 80 mg is more effective than losartan/HCTZ (50/12.5 mg) at the end of the dosing interval. Furthermore, greater reductions in last 6 h mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) are achieved with telmisartan/HCTZ (80/12.5 mg) than with valsartan/HCTZ (160/12.5 mg) in obese patients with type 2 diabetes and hypertension. Recent data from a large group of patients show that telmisartan 80 mg controls the early morning blood pressure surge more effectively than ramipril 5–10 mg and, thus, may have a greater beneficial effect on long-term cardiovascular risk. This supposition is being tested in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) programme
format Text
id pubmed-1993985
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-19939852008-03-06 A Review of Telmisartan in the Treatment of Hypertension: Blood Pressure Control in the Early Morning Hours Gosse, Philippe Vasc Health Risk Manag Review Measurement of blood pressure in the clinic may provide a false impression of blood pressure control. Ambulatory blood pressure monitoring (ABPM) allows the automatic recording of the circadian variation in blood pressure and evaluation of the efficacy of antihypertensive medication throughout the dosing interval. Ambulatory blood pressure provides more effective prediction of cardiovascular risk; blood pressure control at the time of heightened risk in the early morning after waking and before taking the next dose of medication is becoming important in order to improve long-term prognosis. To achieve blood pressure control in the early morning, a long-acting antihypertensive agent is essential. Telmisartan, an angiotensin II receptor blocker, as well as having a terminal elimination halflife of 24 h, has a large volume of distribution due to its high lipophilicity. The efficacy of telmisartan 80 mg monotherapy has been demonstrated using ABPM, with superior reduction in mean values for the last 6 h of the dosing interval compared with ramipril 10 mg and valsartan 80 mg. In addition, telmisartan 80 mg provides superior blood pressure control after a missed dose compared with valsartan 160 mg. When combined with hydrochlorothiazide (HCTZ) 12.5 mg, telmisartan 40 mg and 80 mg is more effective than losartan/HCTZ (50/12.5 mg) at the end of the dosing interval. Furthermore, greater reductions in last 6 h mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) are achieved with telmisartan/HCTZ (80/12.5 mg) than with valsartan/HCTZ (160/12.5 mg) in obese patients with type 2 diabetes and hypertension. Recent data from a large group of patients show that telmisartan 80 mg controls the early morning blood pressure surge more effectively than ramipril 5–10 mg and, thus, may have a greater beneficial effect on long-term cardiovascular risk. This supposition is being tested in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) programme Dove Medical Press 2006-09 2006-09 /pmc/articles/PMC1993985/ /pubmed/17326326 Text en © 2006 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Gosse, Philippe
A Review of Telmisartan in the Treatment of Hypertension: Blood Pressure Control in the Early Morning Hours
title A Review of Telmisartan in the Treatment of Hypertension: Blood Pressure Control in the Early Morning Hours
title_full A Review of Telmisartan in the Treatment of Hypertension: Blood Pressure Control in the Early Morning Hours
title_fullStr A Review of Telmisartan in the Treatment of Hypertension: Blood Pressure Control in the Early Morning Hours
title_full_unstemmed A Review of Telmisartan in the Treatment of Hypertension: Blood Pressure Control in the Early Morning Hours
title_short A Review of Telmisartan in the Treatment of Hypertension: Blood Pressure Control in the Early Morning Hours
title_sort review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993985/
https://www.ncbi.nlm.nih.gov/pubmed/17326326
work_keys_str_mv AT gossephilippe areviewoftelmisartaninthetreatmentofhypertensionbloodpressurecontrolintheearlymorninghours
AT gossephilippe reviewoftelmisartaninthetreatmentofhypertensionbloodpressurecontrolintheearlymorninghours